592 completed, 127 unknown, 73 recruiting, 65 terminated. 298 Not applicable, 147 Phase 3, 143 Phase 2, 136 Phase 4, 60 Phase 1.
Follow Glaucoma, Open-Angle: new trials by email Literature Review of Glaucoma, Open-Angle trials Research Report on Glaucoma, Open-Angle
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution - Glaucoma, Glaucoma, Open-Angle | Phase 4 | Not yet recruiting | Tulane University | 60 | 2027-11-01 | 2026-10-13 |
| Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) Nicotinamide, Standard Glaucoma Therapy - Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG) | Phase 2 | Not yet recruiting | University of Chicago | 96 | 2027-06-01 | 2026-10-13 |
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-09-29 |
| Combined Phacoemulsification-Goniotomy in Primary Open-Angle and Primary Angle-Closure Glaucoma Combined Phacoemulsification and Goniotomy - Primary Open-Angle Glaucoma, Primary Angle-Closure Glaucoma | Not applicable | Not yet recruiting | Assiut University | 70 | 2026-10-01 | 2026-09-16 |
| Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed. GORE Glaucoma Drainage Implant - Glaucoma, Primary Open Angle | Not applicable | Not yet recruiting | Gore Ophthalmic | 70 | 2026-10-01 | 2026-10-19 |
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| Testing a Reading Module to Improve Reading Skills and Quality of Life in Glaucoma Patients Reading Rehabilitation Module - Primary Open Angle Glaucoma (POAG), Juvenile Open Angle Glaucoma | Not applicable | Not yet recruiting | Universiti Sains Malaysia | 100 | 2026-09-01 | 2026-08-12 |
| A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG) | Recruiting | Massachusetts General Hospital | 90 | 2026-08-18 | 2026-08-25 | |
| PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract PEI combined with gonioscopy-assisted trabeculotomy, PEI combined with conventional topical IOP-lowering medications - Primary Open Angle Glaucoma and Cataracts | Not applicable | Recruiting | Nanfang Hospital, Southern Medical University | 106 | 2026-07-15 | 2026-07-14 |
| Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries Goniotomy - Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG) | Not applicable | Not yet recruiting | Henry Ford Health System | 132 | 2026-07-01 | 2026-06-11 |
| Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH Preservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension | Phase 4 | Active not recruiting | Tecnoquimicas | 140 | 2026-06-10 | 2026-07-08 |
| A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®) - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | Phase 3 | Recruiting | YS Life Science Co., Ltd. | 600 | 2026-06-02 | 2026-09-23 |
| Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma Product DNN.31.19.026, COSOPT® - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 3 | Not yet recruiting | Ache Laboratorios Farmaceuticos S.A. | 336 | 2026-06-01 | 2026-06-01 |
| Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital genotyping assay by polymerase chain reaction - Primary Open Angle Glaucoma (POAG) | Not yet recruiting | Sohag University | 80 | 2026-06-01 | 2025-08-13 | |
| iDose TR Administration in an Office-Based Surgery Setting iDose TR (travoprost intracameral implant) 75 µg - Open Angle Glaucoma (OAG), Ocular Hypertension (OHT) | Recruiting | Glaukos Corporation | 30 | 2026-05-13 | 2026-09-30 | |
| Goniotomy in Primary Congenital Glaucoma Primary Congenital Glaucoma, Goniotomy | Not yet recruiting | Sun Yat-sen University | 120 | 2026-05-01 | 2026-04-24 | |
| Direct vs Standard SLT for Glaucoma: A Noninferiority Trial Direct Selective laser Trabeculoplasty - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Not applicable | Recruiting | Medical University of South Carolina | 172 | 2026-04-27 | 2026-05-06 |
| Combined Non-Invasive Brain and Visual Stimulation for Vision Improvement NIBS, VTS, NIBS+VTS - Glaucoma Open-Angle | Not applicable | Not yet recruiting | The Hong Kong Polytechnic University | 56 | 2026-04-20 | 2026-03-24 |
| Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma Digital Reminder Intervention - Primary Open-Angle Glaucoma (POAG) | Not applicable | Not yet recruiting | Sakarya Yenikent State Hospital | 84 | 2026-04-01 | 2026-03-18 |
Showing 20 of 953. Sign in to see all of them.
Ocular Hypertension (428) · Glaucoma (298) · Cataract (44) · Hydrophthalmos (37) · Exfoliation Syndrome (36) · Low Tension Glaucoma (30) · Glaucoma, Angle-Closure (22) · Hypertension (19) · Eye Diseases (17) · Glaucoma, Neovascular (10) · Glaucoma-Related Pigment Dispersion Syndrome (6) · Patient Compliance (5) · Sleep Apnea, Obstructive (5) · Choroidal Effusions (4)
Eye Diseases (936) · Glaucoma (655) · Ocular Hypertension (525) · Lens Diseases (44) · Uveal Diseases (42) · Eye Abnormalities (41) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (39) · Iris Diseases (38) · Congenital Abnormalities (37) · Infant, Newborn, Diseases (37) · Optic Nerve Diseases (33) · Cardiovascular Diseases (23) · Vascular Diseases (23) · Nervous System Diseases (14)
Latanoprost (103) · Timolol (79) · Travoprost (65) · Ophthalmic Solutions (49) · Bimatoprost (40) · brinzolamide (35) · Trabeculectomy (32) · Brimonidine Tartrate (29) · Cataract Extraction (26) · dorzolamide (22) · Phacoemulsification (20) · dorzolamide-timolol combination (20) · Duotrav (18) · netarsudil (16) · tafluprost (16)
Alcon Research (104) · Allergan (48) · Glaukos Corporation (43) · Aerie Pharmaceuticals (18) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (15) · Wills Eye (15) · Santen Pharmaceutical Co., Ltd. (13) · Sensimed AG (11) · Universitaire Ziekenhuizen KU Leuven (11) · Medical University of Vienna (10) · Sight Sciences, Inc. (10) · iSTAR Medical (10) · AbbVie (9) · Santen Inc. (9) · Aristotle University Of Thessaloniki (7)
United States (350) · Germany (66) · Spain (47) · Canada (41) · China (40) · Italy (36) · Egypt (35) · United Kingdom (34) · France (33) · Austria (29) · Belgium (26) · Switzerland (23) · Armenia (22) · Poland (22) · South Korea (22)
Ingeborg Stalmans, MD, PhD (7) · William C. Stewart, MD (7) · Theresa Heah, MD (6) · Zubair Hussain, PhD (6) · Lilit A Voskanyan, MD, PhD (5) · Michelle Chen, PhD (5) · Theresa Landry (5) · Jeff Wells, PharmD, MBA (4) · Jeffrey L Goldberg, MD PhD (4) · Kerry Stephens, O.D. (4)
PMID 35943114, PMID 36912740, PMID 19427617, PMID 35643967, PMID 12049574, PMID 19476406, PMID 22427577, PMID 23557744, PMID 23746612, PMID 25358735, PMID 27117781, PMID 27769587, PMID 28551166, PMID 29194198, PMID 29267575, PMID 32166538, PMID 34003939, PMID 34433548, PMID 35076329, PMID 36378864, PMID 37793935, PMID 38985408, PMID 39240530, PMID 39663002, PMID 40408035, PMID 10201583, PMID 10206571, PMID 10366081, PMID 10549639, PMID 10664926, PMID 10922206, PMID 11006239, PMID 11146740, PMID 11165541, PMID 11235540, PMID 11589866, PMID 11815354, PMID 12126947, PMID 12383810, PMID 12395089, PMID 12511365, PMID 12614754, PMID 12640353, PMID 12745004, PMID 12809158, PMID 12809160, PMID 12928267, PMID 14509472, PMID 1454314, PMID 14736774
2014 (3), 2023 (3), 2008 (2), 2015 (2), 2016 (2), 2018 (2), P30AG022838 (2), UL1TR001082 (2), 2009 (1), 2017 (1), 2019 (1), 8KL2TR000112-05 (1), K23EY022659 (1), K23EY026098 (1), R00EY033027 (1)